Cargando…
New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment
Cancers are defined by genetic defects, which underlines the prospect of using gene therapy in patient care. During the past decade, CRISPR technology has rapidly evolved into a powerful gene editing tool with high fidelity and precision. However, one of the impediments slowing down the clinical tra...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779094/ https://www.ncbi.nlm.nih.gov/pubmed/36555398 http://dx.doi.org/10.3390/ijms232415758 |
_version_ | 1784856525245775872 |
---|---|
author | Yan, Biying Liang, Yaxuan |
author_facet | Yan, Biying Liang, Yaxuan |
author_sort | Yan, Biying |
collection | PubMed |
description | Cancers are defined by genetic defects, which underlines the prospect of using gene therapy in patient care. During the past decade, CRISPR technology has rapidly evolved into a powerful gene editing tool with high fidelity and precision. However, one of the impediments slowing down the clinical translation of CRISPR-based gene therapy concerns the lack of ideal delivery vectors. Extracellular vesicles (EVs) are nano-sized membrane sacs naturally released from nearly all types of cells. Although EVs are secreted for bio-information conveyance among cells or tissues, they have been recognized as superior vectors for drug or gene delivery. Recently, emerging evidence has spotlighted EVs in CRISPR delivery towards cancer treatment. In this review, we briefly introduce the biology and function of the CRISPR system and follow this with a summary of current delivery methods for CRISPR applications. We emphasize the recent progress in EV-mediated CRISPR editing for various cancer types and target genes. The reported strategies for constructing EV-CRISPR vectors, as well as their limitations, are discussed in detail. The review aims to throw light on the clinical potential of engineered EVs and encourage the expansion of our available toolkit to defeat cancer. |
format | Online Article Text |
id | pubmed-9779094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97790942022-12-23 New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment Yan, Biying Liang, Yaxuan Int J Mol Sci Review Cancers are defined by genetic defects, which underlines the prospect of using gene therapy in patient care. During the past decade, CRISPR technology has rapidly evolved into a powerful gene editing tool with high fidelity and precision. However, one of the impediments slowing down the clinical translation of CRISPR-based gene therapy concerns the lack of ideal delivery vectors. Extracellular vesicles (EVs) are nano-sized membrane sacs naturally released from nearly all types of cells. Although EVs are secreted for bio-information conveyance among cells or tissues, they have been recognized as superior vectors for drug or gene delivery. Recently, emerging evidence has spotlighted EVs in CRISPR delivery towards cancer treatment. In this review, we briefly introduce the biology and function of the CRISPR system and follow this with a summary of current delivery methods for CRISPR applications. We emphasize the recent progress in EV-mediated CRISPR editing for various cancer types and target genes. The reported strategies for constructing EV-CRISPR vectors, as well as their limitations, are discussed in detail. The review aims to throw light on the clinical potential of engineered EVs and encourage the expansion of our available toolkit to defeat cancer. MDPI 2022-12-12 /pmc/articles/PMC9779094/ /pubmed/36555398 http://dx.doi.org/10.3390/ijms232415758 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yan, Biying Liang, Yaxuan New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title | New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title_full | New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title_fullStr | New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title_full_unstemmed | New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title_short | New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment |
title_sort | new therapeutics for extracellular vesicles: delivering crispr for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779094/ https://www.ncbi.nlm.nih.gov/pubmed/36555398 http://dx.doi.org/10.3390/ijms232415758 |
work_keys_str_mv | AT yanbiying newtherapeuticsforextracellularvesiclesdeliveringcrisprforcancertreatment AT liangyaxuan newtherapeuticsforextracellularvesiclesdeliveringcrisprforcancertreatment |